Prime Medicine Gets FDA Green Light for Gene Editing Study
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
Stocks · News reference
Prime Medicine shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $9 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday
Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and INLIF surged on revenue growth.
Prime Medicine shares are trading higher after the company announced the FDA clearance of its Investigational New Drug application for PM647 in Alpha-1 antitrypsin deficiency.